Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

KD-3010

Name: KD-3010
Brand: TargetMol
SKU: T11747
Rating: 4.5 (1 reviews)

Copy Product Info

😃Good

Catalog No. T11747Cas No. 934760-92-6

KD-3010 (Kalypsys) is an orally active potent and selective PPARδ agonist for the study of liver injury.

KD-3010

Copy Product Info

😃Good

Purity: 99.61%

Catalog No. T11747Cas No. 934760-92-6

KD-3010 (Kalypsys) is an orally active potent and selective PPARδ agonist for the study of liver injury.

Pack Size	Price	USA Warehouse	Global Warehouse
25 mg	$1,820	8-10 weeks	8-10 weeks
50 mg	$2,380	8-10 weeks	8-10 weeks
100 mg	$3,100	8-10 weeks	8-10 weeks

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.However, due to objective factors, there is a small probability that the synthesis may not be successful during the R&D process. We appreciate your understanding.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.61%

Appearance:Solid

Color:Yellow

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description

KD-3010 (Kalypsys) is an orally active potent and selective PPARδ agonist for the study of liver injury.

In vivo

To investigate the potential benefits of PPARδ agonists in experimental liver fibrosis, mice are orally treated with a PPARδ agonist, KD-3010, or the well-validated PPARδ agonist GW501516. In liver fibrosis induced by carbon tetrachloride (CCl4) or bile duct ligation (BDL), KD-3010, but not GW501516, demonstrates hepatoprotective and antifibrotic effects. The induction of liver injury is achieved through repeated injections of CCl4, and mice are orally administered vehicle, the widely used PPARδ agonist GW501516, or the PPARδ agonist KD-3010 on a daily basis. Control mice injected with oil do not exhibit liver damage. Liver injury, characterized by hepatocyte death and inflammation, is observed in the group treated with vehicle or GW501516 and injected with CCl4 based on H&E-stained liver sections, but this injury is markedly reduced in the KD-3010-treated group[1].

Chemical Properties

Molecular Weight	670.72
Formula	C₃₀H₃₃F₃N₂O₈S₂
Cas No.	934760-92-6
Smiles	S(=O)(=O)(O)C1=CC=C(C)C=C1.S(=O)(=O)(C1=C2C(C[C@H](C(O)=O)C2)=CC=C1)N3[C@H](C)CN(C[C@@H]3C)C4=CC=C(OC(F)(F)F)C=C4
Relative Density.	no data available

Storage & Solubility Information

Storage

store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc